Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation

Heng Chi; David Wong; Jie Peng; Jiawei Cao; Stijn Van Hees; Thomas Vanwolleghem; Xun Qi; Liang Chen; Jordan J Feld; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen

doi:10.1093/cid/cix353

Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation

Clin Infect Dis. 2017 Aug 15;65(4):680-683. doi: 10.1093/cid/cix353.

Authors

Heng Chi¹, David Wong², Jie Peng³, Jiawei Cao³, Stijn Van Hees^{1

4}, Thomas Vanwolleghem^{1

4}, Xun Qi⁵, Liang Chen⁵, Jordan J Feld², Robert J de Knegt¹, Bettina E Hansen^{1

2}, Harry L A Janssen^{1

2}

Affiliations

¹ Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, The Netherlands.
² Toronto Centre for Liver Disease, University Health Network, Toronto General Hospital, University of Toronto, Ontario, Canada.
³ Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
⁴ Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Belgium.
⁵ Department of Hepatitis Disease, Shanghai Public Health Clinical Center, Fudan University, China.

PMID: 28575292
DOI: 10.1093/cid/cix353

Abstract

In 70 chronic hepatitis B patients with hepatitis B surface antigen seroclearance during nucleos(t)ide analogue therapy, response was sustained in all 54 patients who discontinued treatment. Clinically significant relapses as indicated by high hepatitis B virus DNA and ALT levels were not observed. Anti-HBs positivity may not be required to ensure sustained off-treatment response.

Keywords: HBsAg negative; chronic hepatitis B; nucleos(t)ide analogue; off-treatment response; treatment discontinuation.

Publication types

Multicenter Study
Observational Study

MeSH terms

Adult
Antiviral Agents / therapeutic use*
DNA, Viral
Female
Hepatitis B Antigens / blood*
Hepatitis B, Chronic / drug therapy*
Hepatitis B, Chronic / epidemiology
Hepatitis B, Chronic / virology*
Humans
Male
Middle Aged
Nucleosides / therapeutic use
Sustained Virologic Response*
Viral Load
Young Adult

Substances

Antiviral Agents
DNA, Viral
Hepatitis B Antigens
Nucleosides